Esperion's cholesterol drug succeeds in late-stage study

(Reuters) – Esperion Therapeutics Inc said on Wednesday a late-stage trial of its experimental oral drug met the main goal of reducing cholesterol by 28 percent in patients suffering from, or at a high risk of, an artery-clogging heart disease.


Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *